Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation

Viola W Zhu,1 Alexa B Schrock,2 Thangavijayan Bosemani,3 Bryan S Benn,4 Siraj M Ali,2 Sai-Hong Ignatius Ou1 1Chao Family Comprehensive Cancer Center, Division of Hematology/Oncology, Department of Medicine, University of California, Irvine School of Medicine, Orange, CA, USA; 2Clinical Development,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Zhu VW, Schrock AB, Bosemani T, Benn BS, Ali SM, Ou SI
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2018
Materias:
ALK
Acceso en línea:https://doaj.org/article/cf8d2154987d49228f29c29d9f614742
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!